Phase I/II Trial of Mobocertinib in EGFR ex20ins+ Advanced NSCLC: Analysis of Patient Cohort With Disease Control on Prior EGFR TKI Therapy

Free video from Clinical Care Options (CCO) featuring expert discussion of the latest updates in immunotherapy for early-stage NSCLC

Justin F. Gainor, MD
Program Director Stephen V. Liu, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 10, 2022 Expired: January 9, 2023

Drs Enriqueta Felip and Alexander Spira discuss the emerging role of EGFR exon 20 insertion mutations in the management of advanced NSCLC, from Clinical Care Options (CCO)

Enriqueta Felip, MD Alexander Spira, MD, PhD, FACP Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Released: December 28, 2021 Expired: December 27, 2022

From Clinical Care Options (CCO), experts review key data in genitourinary, gastrointestinal, breast, and lung cancers presented at the ESMO 2021 congress

Eva M. Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD Vamsidhar Velcheti, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: December 15, 2021 Expired: December 14, 2022

In this commentary from Clinical Care Options (CCO), Dr. David Planchard provides an overview of the status of EGFR TKI combination therapy for newly diagnosed EGFR-mutated advanced NSCLC.

David Planchard, MD, PhD Released: December 3, 2021